These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1. Mrhalova M; Kodet R Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059 [TBL] [Abstract][Full Text] [Related]
23. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer. Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623 [TBL] [Abstract][Full Text] [Related]
24. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma. El-Hafez AA; El Aaty Shawky A; Hasan B Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005 [TBL] [Abstract][Full Text] [Related]
26. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. Ravikumar G; Ananthamurthy A J Cancer Res Ther; 2014; 10(3):671-5. PubMed ID: 25313758 [TBL] [Abstract][Full Text] [Related]
27. Cyclin D1 gene amplification is highly homogeneous in breast cancer. Burandt E; Grünert M; Lebeau A; Choschzick M; Quaas A; Jänicke F; Müller V; Scholz U; Bokemeyer C; Petersen C; Geist S; Paluchowski P; Wilke C; Heilenkötter U; Simon R; Sauter G; Wilczak W Breast Cancer; 2016 Jan; 23(1):111-119. PubMed ID: 24862872 [TBL] [Abstract][Full Text] [Related]
28. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Agarwal R; Gonzalez-Angulo AM; Myhre S; Carey M; Lee JS; Overgaard J; Alsner J; Stemke-Hale K; Lluch A; Neve RM; Kuo WL; Sorlie T; Sahin A; Valero V; Keyomarsi K; Gray JW; Borresen-Dale AL; Mills GB; Hennessy BT Clin Cancer Res; 2009 Jun; 15(11):3654-62. PubMed ID: 19470724 [TBL] [Abstract][Full Text] [Related]
29. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. Jares P; Rey MJ; Fernández PL; Campo E; Nadal A; Muñoz M; Mallofré C; Muntané J; Nayach I; Estapé J; Cardesa A J Pathol; 1997 Jun; 182(2):160-6. PubMed ID: 9274525 [TBL] [Abstract][Full Text] [Related]
30. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701 [TBL] [Abstract][Full Text] [Related]
31. CCND1 copy number increase and cyclin D1 expression in acral melanoma: a comparative study of fluorescence in situ hybridization and immunohistochemistry in a Chinese cohort. Liu J; Yu W; Gao F; Qi S; Du J; Ma X; Zhang Y; Zheng J; Su J Diagn Pathol; 2021 Jul; 16(1):60. PubMed ID: 34225728 [TBL] [Abstract][Full Text] [Related]
32. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry. Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470 [TBL] [Abstract][Full Text] [Related]
33. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Reed W; Flørems VA; Holm R; Hannisdal E; Nesland JM Virchows Arch; 1999 Aug; 435(2):116-24. PubMed ID: 10599310 [TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Miyamoto R; Uzawa N; Nagaoka S; Hirata Y; Amagasa T Oral Oncol; 2003 Sep; 39(6):610-8. PubMed ID: 12798405 [TBL] [Abstract][Full Text] [Related]
35. Detection of CHK1 and CCND1 gene copy number changes in breast cancer with dual-colour fluorescence in-situ hybridization. Mu K; Li L; Yang Q; Zhang T; Gao P; Meng B; Liu Z; Wang Y; Zhou G Histopathology; 2011 Mar; 58(4):601-7. PubMed ID: 21401699 [TBL] [Abstract][Full Text] [Related]
36. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer]. Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562 [TBL] [Abstract][Full Text] [Related]
37. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Reis-Filho JS; Milanezi F; Carvalho S; Simpson PT; Steele D; Savage K; Lambros MB; Pereira EM; Nesland JM; Lakhani SR; Schmitt FC Breast Cancer Res; 2005; 7(6):R1028-35. PubMed ID: 16280056 [TBL] [Abstract][Full Text] [Related]
38. Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer. Kronblad A; Helczynska K; Nielsen NH; Påhlman E; Emdin S; Påhlman S; Landberg G In Vivo; 2003; 17(4):311-8. PubMed ID: 12929585 [TBL] [Abstract][Full Text] [Related]
39. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis. Xu XL; Chen SZ; Chen W; Zheng WH; Xia XH; Yang HJ; Li B; Mao WM Breast Cancer Res Treat; 2013 Jun; 139(2):329-39. PubMed ID: 23670132 [TBL] [Abstract][Full Text] [Related]
40. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Jirström K; Stendahl M; Rydén L; Kronblad A; Bendahl PO; Stål O; Landberg G Cancer Res; 2005 Sep; 65(17):8009-16. PubMed ID: 16140974 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]